Compensation award — excluded from discretionary-purchase analysis.
Traded Jun 15, 2026 · Filed Jun 17, 2026
Vertex Pharmaceuticals's and CMO sold $1.83M of Vertex Pharmaceuticals shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$1,827,900
Shares × reported transaction price
42 days after results of May 4, 2026, 49 days before results of Aug 3, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $450.46 on Jun 15, 2026, 23% above its 52-week low and 10% below its high, after a 6% rise over the previous 30 trading days
52-week range $366.54 (Aug 8, 2025) to $499.17 (Mar 10, 2026), 63% of the way up, from 251 adjusted closes. 30 trading days earlier: $423.92 on May 1, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +6.3% | -1.7% | +8.0% |
| 30 days | +6.4% | -0.6% | +7.0% |
| 90 days | +13.7% | +1.0% | +12.7% |
Past results only. Not a forecast.
Compensation award — excluded from discretionary-purchase analysis.
Compensation award — excluded from discretionary-purchase analysis.
Officer sold ~$787K of Vertex Pharmaceuticals
Scheduled in advance